Part,  Chapter, Paragraph

  1    I,     2. 10.  4(11)|                               Her effect van elektronisch voorschrijven
  2    I,     2. 10.  4(11)|          barcodescanning op het optreden van medicatie toedienfouten”,
  3    I,     3.  4        |              Henkens K (2001): De timing van het eerste kind in Nederland
  4    I,     3.  4        |                  Meningen en opvattingen van de bevolking over aspecten
  5    I,     3.  4        |                  bevolking over aspecten van het bevolkingsvraagstuk
  6   II,     4.  1        |             latter by means of the GALI (van Oyen et al, 2006). The HLY
  7   II,     4.  3        |                and Human Services: 34.~ ~Van Oyen, H., J. van der Heyden,
  8   II,     4.  3        |                   34.~ ~Van Oyen, H., J. van der Heyden, et al. (2006):
  9   II,     5.  2.  6    |                Aravanis C, Blackburn HW, Van Buchem FS, Buzina R, Djordjević
 10   II,     5.  5.  1    |                41.~ ~Värnik A, Kölves K, van der Feltz-Cornelius CM, Mar , (
 11   II,     5.  5.  3    |            Berkman et al, 2007; Hoek and van Hoeken, 2003).~ ~Reviewed
 12   II,     5.  5.  3    |                  and studies by Hoek and van Hoeken (2003) for several
 13   II,     5.  5.  3    |                  and studies by Hoek and van Hoeken (2003) for several
 14   II,     5.  5.  3    |                 25 remains low (Hoek and van Hoeken, 2003). An average
 15   II,     5.  5.  3    |               number is rising (Hoek and van Hoeken, 2003). Time trends
 16   II,     5.  5.  3    |            constant until 1990 (Hoek and van Hoeken, 2003). Hoek and
 17   II,     5.  5.  3    |                  Hoeken, 2003). Hoek and van Hoeken (2003) reported a
 18   II,     5.  5.  3    |                  1 per 100.000 (Hoek and van Hoeken, 2003).~The HBSC (
 19   II,     5.  5.  3    |           Disorder 41:1 92-95.~Hoek H W, van Hoeken D, (2003): Review
 20   II,     5.  5.  3    |                 in people with epilepsy (Van den Broek and Beghi, 2004).
 21   II,     5.  5.  3    |                141-146.~Kotsopoulos IAW, van Merode T, Kessels FGH, et
 22   II,     5.  5.  3    |               338:1715-1722.~Smeets VMJ, van Lierop BAG, Vanhoutvin JPG,
 23   II,     5.  5.  3    |                   accessed 10 May 2005).~Van den Broek M, Beghi E, for
 24   II,     5.  5.  3    |         publication available at http f]~Van Ooteghem P, De Hooghe MB,
 25   II,     5.  5.  3    | Neuroepidemiology 13:220-225.~Vukusic S, Van Bockstael V, Gosselin S,
 26   II,     5.  5.  3    |                   Sutcliffe et al, 1985; van de Vijver et al, 2001),
 27   II,     5.  5.  3    |         Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A (
 28   II,     5.  5.  3    |              Neurology 43(10):1918-1926.~van de Vijver DA, Roos RA, Jansen
 29   II,     5.  6.  3    |                 the elderly (Picavet and van den Bos, 1997). Musculoskeletal
 30   II,     5.  6.  3    |                 most over the age of 70 (van Saase et al, 1989). For
 31   II,     5.  6.  3    |                  can also be considered (van Staa et al, 2001). The lifetime
 32   II,     5.  6.  3    |                  25 and 64 years of age (van den Velden et al, 1991).
 33   II,     5.  6.  6    |              Polder JJ, Koopmanschap MA, van der Maas PJ (1998): Demographic
 34   II,     5.  6.  6    |                   62:644-650~Picavet HS, van den Bos GA (1997): The contribution
 35   II,     5.  6.  6    |                   de Regt EB, Andries F, van Agt HM, Bijl RV, de Boer
 36   II,     5.  6.  6    |                 Ann Rheum Dis 57:649-655~Van den Velden J, De Bakker
 37   II,     5.  6.  6    |                 in de huisartspraktijk~ ~van Saase JL, van Romunde LK,
 38   II,     5.  6.  6    |         huisartspraktijk~ ~van Saase JL, van Romunde LK, Cats A, Vandenbroucke
 39   II,     5.  6.  6    |                 Ann Rheum Dis 48:271-280~van Staa TP, Dennison EM, Leufkens
 40   II,     5.  7.  1    |              2006b; Cirillo et al, 2006; Van Biesen et al, 2007); these
 41   II,     5.  7.  3    |               ESRD (Stengel et al, 2003; van Dijk et al, 2005) After
 42   II,     5.  7.  3    |                  RRT patients (Jager and van Dijk 2007) resulted in a
 43   II,     5.  7.  3    |                 is about 60 cases pmarp (Van der Heijden et al, 2004).
 44   II,     5.  7.  3    |              higher in females (Belgium (Van Biesen et al, 2007) , England (
 45   II,     5.  7.  3    |         differences in patient survival (van Dijk et al, 2007). International
 46   II,     5.  7.  3    |                   and 56%, respectively (Van Dijk et al, 2001).~ ~In
 47   II,     5.  7.  3    |               ESRD (Stengel et al, 2003; van Dijk et al, 2005) After
 48   II,     5.  7.  3    |                  RRT patients (Jager and van Dijk 2007) resulted in a
 49   II,     5.  7.  4    |           general population) (Jager and van Dijk, 2007). Another factor
 50   II,     5.  7.  7    |                  de Vries R, Hillege HL, van Gilst WH, et al (2006):
 51   II,     5.  7.  7    |                 3):394-9.~Gansevoort RT, van der HB, Stegeman CA, de
 52   II,     5.  7.  7    |                 141(2):95-101.~Jager KJ, van Dijk PC (2007): Has the
 53   II,     5.  7.  7    |                  6.~Stengel B, Billon S, van Dijk PC, Jager KJ, Dekker
 54   II,     5.  7.  7    |                PE, O'donoghue DJ, de LS, Van VJ, Klebe B, Middleton R,
 55   II,     5.  8.  7    |                1973-1980.~ ~Mohangoo AD, van der Linden MW, Schellevis
 56   II,     5.  8.  7    |                   Olivieri M, Villani S, Van Sprundel M, Antó JM, and
 57   II,     5.  8.  7    |               Care Med. 172:1139-1145.~ ~Van Schayck CP, Loozen JM, Wagena
 58   II,     5.  8.  7    |                  EJ, Kant I, Huibers MJ, van Amelsvoort LG, Swaen GM,
 59   II,     5.  8.  7    |                LG, Swaen GM, Wouters EF, van Schayck CP. Psychological
 60   II,     5. 10.  7    |              Pumphrey RSH, Stahl Skov P, van Ree R, Vlieg-Boerstra BJ,
 61   II,     5. 10.  7    |                 C, Botjes E, Crevel RWR, van Ree R (2007): The prevalence,
 62   II,     5. 10.  7    |                   Stern M, Ciclitira PJ, Van Eckert R, Feighery C, Janssen
 63   II,     5. 11.  3    |               young healthy populations (van Coevorden et al, 2004).~ ~
 64   II,     5. 11.  7    |               Springer-Verlag, 1991,9.~ ~Van Coevorden AM, Coenraads
 65   II,     5. 15.  1    |                  genetically determined (van Weely and Leufkens, 2004;
 66   II,     5. 15.  6    |              drugs. Available at: htt et~Van Weely S, Leufkens HGM (2004):
 67   II,     8.  2.  1    |                  population (Straetmans, van Schrojenstein Lantman-de
 68   II,     8.  2.  1    |          population and clinical levels (van Schrojenstein Lantman-de
 69   II,     8.  2.  1    |                 For example, Straetmans, van Schrojenstein Lantman-de
 70   II,     8.  2.  1    |           Straetmans, J.M.J.A.A., H.M.J. van Schrojenstein Lantman-de
 71   II,     8.  2.  1    |                    www.eurohealthnet.eu>~Van Schrojenstein Lantman-de
 72   II,     8.  2.  1    |                Research, 51, 6, 427-434.~van Schrojenstein Lantman-de
 73   II,     8.  2.  1    |               press.~Walsh PN, Kerr M.P, van Schrojenstein Lantman-de
 74   II,     8.  2.  1    |                   Linehan, C., Kerr, M., van Schrojenstein Lantman-de
 75   II,     8.  2.  1    |                    Garrido-Cumbrera, M., van Hove, G., Björkman, M.,
 76   II,     9.  1.  1    |               Kuijpers JC, Meershoek AP, van Velzen D (1998): Contribution
 77   II,     9.  1.  1    |               Health Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan
 78   II,     9.  1.  1    |        Pediatrics 2007;120(4):e815-25.~ ~van Roosmalen J, Schuitemaker
 79   II,     9.  1.  1    |                Schuitemaker NW, Brand R, van Dongen PW, Bennebroek Gravenhorst
 80   II,     9.  1.  2    |    supplementation (De Walle and de Jong van den Berg, 2007). Some European
 81   II,     9.  1.  2    |                 17.~De Walle HE, de Jong van den Berg LT (2007): Growing
 82   II,     9.  1.  2    |                Reuvers M, Robert E, Rost van Tonningen M, Scialli A,
 83   II,     9.  3.  2    |                2006) or the Netherlands (van Roosmalen et al, 2002).~ ~
 84   II,     9.  3.  2    |                  impact on their health (Van Reempts, 2007).~ ~A key
 85   II,     9.  3.  2    |               Kuijpers JC, Meershoek AP, van Velzen D (1998): Contribution
 86   II,     9.  3.  2    |                764-70.~ ~Schuitemaker N, van Roosmalen J, Dekker G, van
 87   II,     9.  3.  2    |               van Roosmalen J, Dekker G, van Dongen P, van Geijn H, Bennebroek
 88   II,     9.  3.  2    |                  Dekker G, van Dongen P, van Geijn H, Bennebroek Gravenhorst
 89   II,     9.  3.  2    |               Health Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan
 90   II,     9.  3.  2    |        Pediatrics 2007;120(4):e815-25.~ ~van Roosmalen J, Schuitemaker
 91   II,     9.  3.  2    |                Schuitemaker NW, Brand R, van Dongen PW, Bennebroek Gravenhorst
 92   II,     9.  4.  7    |                De Henauw S., Schroll M., Van Staveren Wa. (2004): Abstract:
 93  III,    10.  1.  3    |             Lopez AD, Rodgers A, Hoorn S van der, Murray CJL et al (2002):
 94  III,    10.  2.  1    |                Arnadottir IB, Ketley CE, Van Loveren C, Seppa L, Cochran
 95  III,    10.  2.  1    |                 Whelton HP, Holbrook WP, van Loveren C, Fernandes B,
 96  III,    10.  2.  1    |                Miermans PJ, Tafforeau J, van der Heyden J (2006): Gezondheidsenquête
 97  III,    10.  2.  1    |                 G, Bueno-de-Mesquita HB, van der Schouw YT, Engeset D,
 98  III,    10.  2.  1    |               Pettersson U, Palmqvist R, Van Guelpen B, Bingham SA, McTaggart
 99  III,    10.  2.  4    |                   Sleegens K, Prince JA, van Duijn CM, Kehoe PG (2005):
100  III,    10.  3.  1    |                available (Babisch, 2008; Van Kempen et al., 2002).~ ~
101  III,    10.  3.  1    |                 SC 1 N 1313.~Kempen EEMM van, Kruize H, Boshuizen HC,
102  III,    10.  3.  1    |               Staatsen BAM, Overveld AJP van, Ameling CB. Trends in the
103  III,    10.  3.  1    |                 R (2003). Kwantificering van gezondheidsrisico’s aan
104  III,    10.  3.  1    |          gezondheidsrisico’s aan de hand van DALYs en externe gezondheidskosten {
105  III,    10.  3.  1    |            Studie uitgevoerd in opdracht van de Vlaamse Milieumaatschappij,
106  III,    10.  3.  1    |                 night. Edited by: Berg M van den. World Health Organization
107  III,    10.  3.  2    |                  Ravindra, K, L Bencs, R van Grieken (2004): Platinum
108  III,    10.  4.  2    |                  recent years~Monitoring~Van Kasteren, 2000;~Richard
109  III,    10.  4.  2    |           Richard et al., 2001;~Fiolet & van Veen, 2001~ ~ ~ ~ ~Pesticides
110  III,    10.  4.  2    |          monitoring by random~sampling~ ~Van der Schee, 2002;~KAP, 2003~ ~
111  III,    10.  4.  2    |                   Taylor & Lehrer, 1996;~van Loveren, 2002; (see~textbox
112  III,    10.  4.  2    |           Richard et al., 2003;~ Sizoo & van Egmond,~2004; WHO, 1998~ ~
113  III,    10.  4.  2    |                Dutch fishing~grounds~ ~ ~Van Apeldoorn et al.,~2004~ ~
114  III,    10.  4.  2    |             grounds~temporarily closed~ ~Van Apeldoorn et al.,~2004~ ~
115  III,    10.  4.  2    |               for scallops in~Scotland~ ~Van Apeldoorn et al.,~2004~ ~
116  III,    10.  4.  2    |              effects~ ~None~ ~Monitoring~Van Apeldoorn et al.,~2004~ ~
117  III,    10.  4.  2    |               1995 in Ireland~Monitoring~Van Apeldoorn et al.,~2004~ ~ ~
118  III,    10.  4.  2    |                not be~eaten~ ~Speijers & van Egmond,~1999~ ~Pyrrolizidine
119  III,    10.  4.  2    |           exposure~Monitoring~Speijers & van Egmond,~1999~ ~Anisatin~
120  III,    10.  5.  2    |                    A large Dutch survey (Van Bergen et al., 2006) brought
121  III,    10.  5.  2    |               Presentation held by Jouke van der Zee et al. (Netherlands
122  III,    10.  5.  2    |                study. BMJ, 317: 576-8.~ ~Van Bergen JEAM et al. (2006):
123  III,    10.  6.  1    |                  risk for victimization (Van Dijk et al, 2005).~ ~Figure
124  III,    10.  6.  1    |          Epidemiology 2006;163:10121017~Van Dijk J, Manchin R, Van Kesteren
125  III,    10.  6.  1    |              1017~Van Dijk J, Manchin R, Van Kesteren J, Hideg G, Nevala
126  III,    10.  6.  2    |                   Geurts JJM, Lahelma E, Van Oyen H, Rasmussen NK, Regidor
127   IV,    11.  1.  4    |                  care in most countries (van Doorslaer et al, 2004).
128   IV,    11.  1.  4    |                   for number of visits) (van Doorslaer et al, 2004).
129   IV,    11.  6.  2    |          expenditure are tax-deductible (Van Doorslaer et al, 1999).
130   IV,    11.  6.  2    |                  without this insurance (van Doorslaer et al, 2004; Mossialos
131   IV,    11.  6.  3    |              lower income (De Graeve and Van Ourti, 2003). The distribution
132   IV,    11.  6.  3    |                regressive (De Graeve and Van Ourti, 2003). In Germany,
133   IV,    11.  6.  3    |           Wagstaff, 2002) (De Graeve and Van Ourti, 2003; Musgrove, 2003).
134   IV,    11.  6.  4    |               risk selection activities (van de Ven et al, 2003). Even
135   IV,    11.  6.  4    |       competition among insurance funds (van de Ven et al 2007).~ ~Table
136   IV,    11.  6.  5    |                  881-906.~ ~De Graeve D, Van Ourti T (2003): The distributional
137   IV,    11.  6.  5    |                  European Communities.~ ~van de Ven W, Beck K et al. (
138   IV,    11.  6.  5    |               Health Policy 65: 75-98.~ ~van Doorslaer E, Koolman X et
139   IV,    11.  6.  5    |              Economics 13(7): 629-647.~ ~van Doorslaer E, Masseria C
140   IV,    11.  6.  5    |                countries. Paris, OECD.~ ~Van Doorslaer E, Wagstaff A
141   IV,    11.  6.  5    |                   103-115.~ ~Wagstaff A, van Doorslaer E et al., Eds. (
142   IV,    13.  2.  3    |               the Netherlands.~ ~Source: Van Kreil et al (2006)~ ~DALYs
143   IV,    13.  9        |             Lopez AD, Rodgers A, Hoorn S van der, Murray CJL et al (2002):
144   IV,    13.  9        |              United Nations, New York.~ ~Van Kreil et al (2006) Our food,